Six months into Schedule III: who actually benefited?
An audit of who gained, who lost, and who is still waiting on federal guidance.
The DEA's reclassification of cannabis to Schedule III went into effect six months ago, and the most striking thing about the change is how unevenly it has been felt. For multistate operators with tax attorneys on retainer, the move was immediate relief — a partial reversal of the 280E tax burden, the most resented provision of federal cannabis policy. For small operators and patient communities, very little has changed.
We surveyed 42 licensed cultivators across nine states, six lab directors, and three patient advocacy groups. Every cultivator over $5M in annual revenue described the rescheduling as a meaningful win. Every operator below that threshold described it as either neutral or, in three cases, modestly negative — the result of unrelated state-level licensing tightening that happened to land in the same quarter.
Lab directors were the most measured group. None we spoke with believed Schedule III had any direct effect on their work. "We test the same samples to the same standards under the same state contracts," one director told us. "Whatever the federal government decides about the molecule doesn't change what the gas chromatograph reads."
“Schedule III gave operators a tax break. It did not, in any practical sense, give patients a new prescription pathway.”
What rescheduling did do is give federal agencies, particularly the FDA, an easier path to issue guidance. Whether they will is another matter. The clinical research backlog is now eighteen months old and growing.
For patients in the medical programs of restrictive states, the news is mixed. Schedule III makes prescribing in principle easier, but very few physicians are credentialed to prescribe and almost none have malpractice carriers that cover it. The gap between what the schedule allows and what the medical system can actually deliver remains the binding constraint.